Latest Conference Coverage

AES Poster Provides Safety Insights to Antiseizure Medication Fenfluramine

Fenfluramine showed a consistent safety profile in treating Lennox-Gastaut syndrome, with common adverse events such as decreased appetite, fatigue, and somnolence.

Research Insights on Developmental Epileptic Encephalopathy With Spike Wave Activation in Sleep: Lekha Rao, MD

The epileptologist at UCLA Health provided perspective on a poster presented at AES 2024 that characterized a specific subgroup of patients with developmental epileptic encephalopathy and their response to certain therapies. [WATCH TIME: 3 minutes]

Claims Analysis Highlights Sleep Apnea Comorbidity as Risk Factor for Increased Mortality in Youths With Epilepsy

Musical Intervention Program May Improve Quality of Life for Pregnant Mothers With Epilepsy

Participants in the intervention group also reported themes of increased connectivity, creativity, and positivity.

Relutrigine Shows Promise in Phase 2 EMBOLD Study of SCN2A-DEE and SCN8A-DEE

Treatment with relutrigine resulted in a 46% placebo-adjusted reduction in motor seizures, along with a well-tolerated safety profile with adverse events that were mild to moderate.

Advancing Epilepsy Treatment and Brain Research Through SEEG: Alexander C. Whiting, MD

The director of epilepsy surgery at Allegheny Health Network talked about research recently presented at AES 2024 on stereo-electroencephalography, a minimally invasive treatment for patients with epilepsy. [WATCH TIME: 7 minutes]

Bexicaserin Shows Promise for Developmental Epileptic Encephalopathies in Phase 1b/2a PACIFIC Extension

Treatment with bexicaserin, a highly selective 5-HT2c receptor superagonist, resulted in reduction in countable motor seizures in patients not previously exposed to the agent.

Interim Analysis Highlights Long-Term Safety of Azetukalner for Focal Epilepsy

In a further date from the ongoing open-label extension of the phase 2b X-TOLE study, results demonstrated that the majority of treatment-emergent adverse events associated with azetukalner were mild or moderate.

Post Hoc Analysis Provides Insights on Low Need for Second Dose of Diazepam Nasal Spray in Pediatric Epilepsy

A recent study presented at AES 2024 showed that fewer than 15% of doses of diazepam nasal spray administered to pediatric patients with epilepsy required a second dose in 24 hours.

Phase 4 EpiCom Study Highlights Potential of CBD in Neuropsychiatric Disorders of Tuberous Sclerosis Complex

CBD maintained a favorable safety profile, with 63% of participants experiencing adverse events such as diarrhea, vomiting, decreased appetite, and lethargy, leading to discontinuation in four patients.

Empowering Patients: Exploring Self-Administration of Rozanolixizumab for Myasthenia Gravis

Rachana K. Gandhi Mehta, MBBS, an assistant professor of neurology at Wake Forest School of Medicine, discussed a new, innovative trial assessing the therapeutic potential of self-administered subcutaneous rozanolixizumab as a treatment for myasthenia gravis.

Higher Dose of Nusinersen Shows Greater Impact on Spinal Muscular Atrophy in Phase 2/3 DEVOTE Study

Findings from a phase 2/3 study demonstrated the efficacy and safety of a higher dose regimen of nusinersen in treating spinal muscular atrophy in both treatment-naïve and previously treated patients.

Phase 2 Galactic53 Data Point to Viltolarsen’s Impact on Respiratory and Motor Function in DMD

These results highlight the age range and ambulation status for which viltolarsen is a key treatment option for DMD patients amenable to exon 53 skipping.

NeuroVoices: Rebecca M. Edelmayer, PhD, on Advancing Blood Biomarkers in Alzheimer Disease for Earlier Diagnosis and Treatment Intervention

The vice president of scientific engagement at the Alzheimer's Association discussed advancements in blood biomarker tests, their use in specialty care, and the development of clinical guidelines for broader integration.

Collaboration and Innovation in Alzheimer Disease Clinical Trial Research: Howard Fillit, MD

The cofounder and chief science officer of the Alzheimer's Drug Discovery Foundation highlighted the critical role of collaboration and innovative diagnostics for advancing Alzheimer disease care. [WATCH TIME: 4 minutes]

Conway CuTS Scale Predicts Impairment Better Than Traditional Scales After Cubital Tunnel Syndrome Surgery

The study, presented at the 2024 AANEM) Annual Meeting, evaluated 52 patients who underwent surgery for carpal tunnel syndrome and explored the comparative effectiveness of the Conway and Zeidman scales in predicting patient outcomes.

Redesigning Clinical Trials in Alzheimer Disease to Promote Diversity and Accessibility

Jessica Langbaum, PhD, the senior director of research strategy at Banner Alzheimer’s Institute, discussed the challenges and opportunities in improving diversity in Alzheimer disease clinical trials.

Study Details of Phase 2 KYSA-6 Trial of CAR-T Therapy in Myasthenia Gravis Presented

The multicenter, 24-week study will feature 20 patients with MG, testing changes on MG-ADL as well as several other secondary outcomes, including patient-reported assessments.

Subcutaneous Efgartigimod Demonstrates Efficacy, Safety in Seronegative Myasthenia Gravis

Overall, subcutaneous efgartigimod was safe and effective in patients with seropositive MG, demonstrated by consistent improvements in Myasthenia Gravis-Activites of Daily Living.

Exploring Blood-Based Biomarkers and Treatment Eligibility in Alzheimer Disease: Gil Rabinovici, MD

The professor of neurology and radiology at University of California, San Francisco, discussed the potential of blood-based biomarkers in Alzheimer treatment eligibility, highlighting current limitations and the importance of safety monitoring. [WATCH TIME: 7 minutes]

Highlights on Exploring Advances in Headache Medicine from AHS Scottsdale 2024: MaryAnn Mays, MD

Phase 2a Trial to Test Effects of Antiseizure Medication Lamotrigine in Dementia With Lewy Bodies

The trial, a 20-week study assessing lamotrigine in DLB, will use change in Clinical Dementia Rating-Sum of Boxes as the primary efficacy end point, with several other notable secondary outcomes.

Medication Compliance High With Self-Administered Ziluocoplan in Myasthenia Gravis

For more than a 2-year treatment period, 95% of patients reported taking at least 95% of their daily medications with zilucoplan.

NeuroVoices: Charbel Moussa, PhD, MBBS, on Therapeutic Potential of Nilotinib in Dementia With Lewy Bodies

The associate professor of neurology at Georgetown University provided clinical insight on the origins of nilotinib and its medicinal promise in treating patients with Dementia with Lewy bodies, a neurodegenerative disorder.

Challenges in Identifying Optimal Candidates for Muscular Dystrophy Gene Therapies: Melissa Spencer, PhD

The professor in residence at UCLA Health discussed the critical considerations when deciding appropriate patients for gene therapies, specifically AAV vectors, in treating muscular dystrophies. [WATCH TIME: 4 minutes]

Need for Better, More Specific Delivery Methods for Gene Therapies in Muscular Dystrophy: Melissa Spencer, PhD

The professor in residence at UCLA Health provided clinical insight on the limitations of certain gene therapy vehicles for muscular dystrophies, and the need for better vectors that are more myotropic. [WATCH TIME: 3 minutes]

Educational Benefits of Flipped Classrooms in Teaching Settings: Lawrence Robinson, MD

The senior scientist at Sunnybrook Research Institute in Toronto, Ontario, provided clinical insight on the advantages of a flipped classroom, and why neurology educators should consider this approach. [WATCH TIME: 2 minutes]

Guidance on Safe Use of Donanemab for Alzheimer Disease in Clinical Settings: Gil Rabinovici, MD

The professor of neurology and radiology at University of California, San Francisco talked about how the new appropriate use recommendations of donanemab aims to safely integrate this anti-amyloid antibody into the clinical practice. [WATCH TIME: 7 minutes]

Clinical Validation and Real-World Impact of PrecivityAD2 Test for Alzheimer Diagnosis: Joel B. Braunstein, MD

The CEO at C2N Diagnostics talked about the clinical utility of the company’s PrecivityAD2 test, which uses the p-tau 217 biomarker and amyloid-β measurements, to increase diagnostic confidence and influence treatment decisions in Alzheimer disease. [WATCH TIME: 7 minutes]

Improving Alzheimer Diagnosis With Innovative Blood-Based Biomarker Tests and BD-Tau: Mike Miller, PhD

The chief operating officer at Quanterix Corporation talked about pioneering ultra-sensitive blood biomarkers for Alzheimer clinical diagnosis, aiming to enhance detection of brain-derived tau and amyloid status with innovative assays. [WATCH TIME: 4 minutes]